Avandia Should Stay On Market With Warnings, Committee Says

FDA's Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees are calling for strengthened warnings for GlaxoSmithKline's type 2 diabetes drug Avandia due to cardiovascular safety concerns, but not its withdrawal from the market

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet